Literature DB >> 28045163

CRISPR-Cas9 technology: applications in genome engineering, development of sequence-specific antimicrobials, and future prospects.

César de la Fuente-Núñez1, Timothy K Lu1.   

Abstract

The development of CRISPR-Cas9 technology has revolutionized our ability to edit DNA and to modulate expression levels of genes of interest, thus providing powerful tools to accelerate the precise engineering of a wide range of organisms. In addition, the CRISPR-Cas system can be harnessed to design "precision" antimicrobials that target bacterial pathogens in a DNA sequence-specific manner. This capability will enable killing of drug-resistant microbes by selectively targeting genes involved in antibiotic resistance, biofilm formation and virulence. Here, we review the origins and mechanistic basis of CRISPR-Cas systems, discuss how this technology can be leveraged to provide a range of applications in both eukaryotic and prokaryotic systems, and finish by outlining limitations and future prospects.

Mesh:

Substances:

Year:  2017        PMID: 28045163     DOI: 10.1039/c6ib00140h

Source DB:  PubMed          Journal:  Integr Biol (Camb)        ISSN: 1757-9694            Impact factor:   2.192


  12 in total

Review 1.  Next-generation precision antimicrobials: towards personalized treatment of infectious diseases.

Authors:  Cesar de la Fuente-Nunez; Marcelo Dt Torres; Francisco Jm Mojica; Timothy K Lu
Journal:  Curr Opin Microbiol       Date:  2017-06-14       Impact factor: 7.934

Review 2.  Ethical Issues of Using CRISPR Technologies for Research on Military Enhancement.

Authors:  Marsha Greene; Zubin Master
Journal:  J Bioeth Inq       Date:  2018-07-02       Impact factor: 1.352

Review 3.  Targeted Therapeutic Strategies in the Battle Against Pathogenic Bacteria.

Authors:  Bingqing Yang; Dan Fang; Qingyan Lv; Zhiqiang Wang; Yuan Liu
Journal:  Front Pharmacol       Date:  2021-05-12       Impact factor: 5.810

4.  Reversal of mcr-1-Mediated Colistin Resistance in Escherichia coli by CRISPR-Cas9 System.

Authors:  Peng Wan; Shiyun Cui; Zhenbao Ma; Lin Chen; Xiaoshen Li; Ruonan Zhao; Wenguang Xiong; Zhenling Zeng
Journal:  Infect Drug Resist       Date:  2020-04-22       Impact factor: 4.003

Review 5.  Endogenous CRISPR-Cas System-Based Genome Editing and Antimicrobials: Review and Prospects.

Authors:  Yingjun Li; Nan Peng
Journal:  Front Microbiol       Date:  2019-10-25       Impact factor: 5.640

6.  Transplantation of hMSCs Genome Edited with LEF1 Improves Cardio-Protective Effects in Myocardial Infarction.

Authors:  Hyun-Min Cho; Kang-Hoon Lee; Yi-Ming Shen; Tae-Jin Shin; Pan-Dong Ryu; Min-Cheol Choi; Kyung-Sun Kang; Je-Yoel Cho
Journal:  Mol Ther Nucleic Acids       Date:  2020-01-18       Impact factor: 8.886

Review 7.  Budding yeast as a factory to engineer partial and complete microbial genomes.

Authors:  Sanjay Vashee; Yonathan Arfi; Carole Lartigue
Journal:  Curr Opin Syst Biol       Date:  2020-09-21

8.  MicroRNAs Are Involved in Maize Immunity Against Fusarium verticillioides Ear Rot.

Authors:  Zijian Zhou; Yan Cao; Tao Li; Xinghao Wang; Jiafa Chen; Hang He; Wen Yao; Jianyu Wu; Huiyong Zhang
Journal:  Genomics Proteomics Bioinformatics       Date:  2020-06-10       Impact factor: 7.691

Review 9.  Strategies to Potentiate Paracrine Therapeutic Efficacy of Mesenchymal Stem Cells in Inflammatory Diseases.

Authors:  Yoojin Seo; Min-Jung Kang; Hyung-Sik Kim
Journal:  Int J Mol Sci       Date:  2021-03-25       Impact factor: 5.923

10.  Genome-scale CRISPR screening identifies cell cycle and protein ubiquitination processes as druggable targets for erlotinib-resistant lung cancer.

Authors:  Jieun Lee; Ahyoung Choi; Sung-Yup Cho; Yukyung Jun; Deukchae Na; Ahra Lee; Giyong Jang; Jee Young Kwon; Jaesang Kim; Sanghyuk Lee; Charles Lee
Journal:  Mol Oncol       Date:  2020-11-28       Impact factor: 7.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.